2024
Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger
Rosenberg S, Zheng Y, Ruddy K, Poorvu P, Snow C, Kirkner G, Meyer M, Tamimi R, Schapira L, Peppercorn J, Come S, Borges V, Warner E, Gelber S, Collins L, Winer E, Partridge A. Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and younger. BMJ Open 2024, 14: e081157. PMID: 38951008, PMCID: PMC11218027, DOI: 10.1136/bmjopen-2023-081157.Peer-Reviewed Original ResearchConceptsYoung Women's Breast Cancer StudyMultisite prospective cohort studyBreast Cancer StudyProspective cohort studyStage 0-IV breast cancerBreast cancerCohort studyOlder womenDied of breast cancerFear of recurrencePatient-reported outcome dataYoung womenCancer studiesClinical data abstractionPost-traumatic stressQuality of lifeImprove careFollow-upPsychosocial outcomesYoung survivorsCommunity sitesBiospecimen collectionUnderstudied populationData abstractionOutcome dataMortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Leone J, Hassett M, Freedman R, Tolaney S, Graham N, Tayob N, Vallejo C, Winer E, Lin N, Leone J. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. JAMA Oncology 2024, 10: 508-515. PMID: 38421673, PMCID: PMC10905378, DOI: 10.1001/jamaoncol.2023.7194.Peer-Reviewed Original ResearchBreast cancer-specific mortalityRisk of breast cancer-specific mortalityBreast cancer-specific mortality riskHR+ breast cancerBreast cancerStage I to III hormone receptor-positive breast cancerEnd Results ProgramPopulation-based dataHormone receptor-positive (HR+) breast cancerCancer-specific mortalityObservational cohort studyResults ProgramRisk of late mortalityHigher stages of diseaseHormone receptor-positive breast cancerReceptor-positive breast cancerMortality riskCohort studyRisk of distant recurrenceStage IIICumulative riskStage IIMultivariate regressionMedian follow-upGrade I tumors
2022
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clinical Cancer Research 2022, 29: 174-182. PMID: 36074155, PMCID: PMC9811155, DOI: 10.1158/1078-0432.ccr-22-1138.Peer-Reviewed Original ResearchConceptsBreast cancer brain metastasesActive brain metastasesObjective response rateCNS objective response rateCancer brain metastasesBrain metastasesT-DXdPatient-derived xenograftsPDX modelsCohort studyTrastuzumab deruxtecanClinical efficacyClinical trialsHER2-positive breast cancer brain metastasesMetastatic HER2-positive breast cancerResponse rateMulti-institutional cohort studyHER2-positive breast cancerRetrospective multi-institutional cohort studyOrthotopic patient-derived xenograftsRetrospective cohort studyProspective clinical trialsSubset of patientsCentral nervous system activityPivotal clinical trials
2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosisAssociation of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2018, 36: jco.2017.76.003. PMID: 29298117, PMCID: PMC5815405, DOI: 10.1200/jco.2017.76.0033.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerTriple-negative breast cancerPrimary triple-negative breast cancerTumor fractionSomatic copy number alterationsCell-free DNABreast cancerSingle tertiary care institutionCopy number alterationsRetrospective cohort studySpecific somatic copy number alterationsTertiary care institutionNovel therapeutic approachesNumber alterationsCfDNA tumor fractionMetastatic survivalPrior chemotherapyTNBC cohortMetastatic settingCohort studyOverall survivalCancer Genome AtlasClinicopathologic factorsWorse survivalPrimary tumor
2017
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
Luis I, Guo H, Barry W, Krop I, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff S, Tung N, Winer E, Lin N, Freedman R. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2017, 35: 1034-1034. DOI: 10.1200/jco.2017.35.15_suppl.1034.Peer-Reviewed Original ResearchMetastatic breast cancerOverall response ratePhase II studyStable diseasePertuzumab exposureAdverse eventsII studyCohort AHuman epidermal growth factor receptorActivity of eribulinDose of eribulinFrequent grade 3First-line settingMost adverse eventsAnti-HER2 therapyCorrelative studiesEpidermal growth factor receptorCell-free DNAGrowth factor receptorHematologic toxicityCohort studyOverall survivalPartial responseCohort BSingle center
2016
Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study
Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. The Breast 2016, 30: 136-140. PMID: 27721193, DOI: 10.1016/j.breast.2016.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMiddle AgedNeutropeniaPaclitaxelPractice Patterns, Physicians'Retrospective StudiesYoung AdultConceptsGranulocyte-colony stimulating factorDose-dense paclitaxelTreatment delayGroup 1High baseline absolute neutrophil countBaseline absolute neutrophil countSingle-institution retrospective studyDana-Farber Cancer InstituteStimulating factorRoutine G-CSFPercent of patientsRetrospective cohort studyAbsolute neutrophil countMajority of patientsAdverse eventsCohort studyNeutrophil countTreatment cessationProspective studyRetrospective studyT therapyBreast cancerGroup 2PatientsCancer Institute
2015
Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer
Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3809-3815. PMID: 25930247, PMCID: PMC4598267, DOI: 10.1245/s10434-015-4572-6.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyBody Mass IndexBreast NeoplasmsDecision MakingDirective CounselingFearFemaleGenes, BRCA1Genes, BRCA2Genetic TestingHumansLymphatic MetastasisMastectomy, SegmentalMutationNeoplasm StagingParityPatient ParticipationProphylactic Surgical ProceduresReceptor, ErbB-2RecurrenceTumor BurdenYoung AdultConceptsBreast-conserving surgeryContralateral prophylactic mastectomyEarly-stage breast cancerUnilateral mastectomyBreast cancerYoung womenProphylactic mastectomyUnilateral stage ILarger tumor sizeOngoing cohort studyGood psychosocial supportResultsMedian ageClinical characteristicsCohort studyHER2 positivityNodal involvementLocal therapyLower BMITumor sizeBRCA mutationsPatient-driven decisionSurgical decisionMethodsAs partMultinomial logistic regressionStage ISurgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals Of Surgical Oncology 2015, 22: 4280-4286. PMID: 25893416, PMCID: PMC4801503, DOI: 10.1245/s10434-015-4570-8.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceBreast-conserving surgeryInitial breast-conserving surgeryLocoregional recurrenceMargin statusLobular carcinomaBreast tumor recurrenceRetrospective cohort studyPositive surgical marginsInvasive lobular carcinomaMedian followInitial surgeryMultimodality therapyCohort studyFurther surgeryAdditional surgeryClinicopathologic dataSurgical marginsSurgical optionsNegative marginsTumor sizeCancer CenterClose marginsConsensus guidelinesTumor recurrenceVariation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study
Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi‐institutional study. Cancer 2015, 121: 1937-1948. PMID: 25757412, PMCID: PMC4457605, DOI: 10.1002/cncr.29310.Peer-Reviewed Original ResearchConceptsStage I breast cancerI breast cancerHuman epidermal growth factor receptor 2Breast cancerAdjuvant chemotherapyIntensive regimensNational Comprehensive Cancer Network centersEpidermal growth factor receptor 2Choice of regimenHER2-negative diseaseHER2-positive diseaseCombination of docetaxelPercentage of patientsProspective cohort studyType of chemotherapyGrowth factor receptor 2Time of diagnosisAmerican Joint CommitteeMultivariable logistic regressionFactor receptor 2Multi-institutional studyCommon regimensChemotherapy regimensIntensive chemotherapyCohort study
2014
Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study
Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. Journal Of Clinical Oncology 2014, 32: 2142-2150. PMID: 24888816, PMCID: PMC4076026, DOI: 10.1200/jco.2013.53.1608.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm StagingPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTrastuzumabTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesConceptsDistant relapse-free survivalBN0M0 breast cancerHER2-negative tumorsBreast cancerT1a tumorsCohort studyT1b tumorsSurvival outcomesHR-positive/HER2-negative tumorsTumor subtypesNational Comprehensive Cancer Network databaseHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusHER2-negative breast cancerNode-negative breast cancerHormone receptorsConsideration of chemotherapyHER2-negative diseasePercent of patientsReceipt of chemotherapyNonrandomized cohort studyProspective cohort studyRelapse-free survivalRate of recurrenceMulti-institutional study
2013
Breast cancer presentation and diagnostic delays in young women
Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women. Cancer 2013, 120: 20-25. PMID: 24347383, DOI: 10.1002/cncr.28287.Peer-Reviewed Original ResearchConceptsCare delaysSymptoms of cancerBreast cancerFirst visitYoung womenMulticenter cohort studyMedical record reviewPatient's first visitBreast cancer presentationBreast abnormalitiesFirst signOwn breast cancerHealth care providersMost young womenPoor financial statusCancer presentationCohort studyDiagnostic delayRecord reviewTumor characteristicsPoor outcomeSystemic symptomsDisease stageEligible participantsExamination abnormalitiesChoosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.
Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer. Journal Of Clinical Oncology 2013, 31: 6507-6507. DOI: 10.1200/jco.2013.31.15_suppl.6507.Peer-Reviewed Original ResearchBreast cancerYoung womenSurgical decisionStage IMulti-center cohort studyEstrogen receptor-positive tumorsReceptor-positive tumorsFinal multivariable modelFear of recurrenceDefinitive surgeryNodal involvementCohort studyMedian ageBilateral mastectomyER statusMultivariable analysisLower BMIPositive tumorsTumor sizeSurgical choiceOvarian cancerTumor gradeMultivariable modelMastectomyAge 40Long‐Term Risk Perceptions of Women With Ductal Carcinoma In Situ
Ruddy KJ, Meyer ME, Giobbie‐Hurder A, Emmons KM, Weeks JC, Winer EP, Partridge AH. Long‐Term Risk Perceptions of Women With Ductal Carcinoma In Situ. The Oncologist 2013, 18: 362-368. PMID: 23568001, PMCID: PMC3639521, DOI: 10.1634/theoncologist.2012-0376.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerDuctal carcinomaLifetime riskFuture breast cancer eventsHistory of DCISBreast cancer eventsTime of diagnosisLong-term followLongitudinal cohort studyFuture breast cancerWorse financial statusCohort studyMedian timeCancer eventsDCISOnly predictorModerate riskMultivariate modelCancerWomenDiagnosisRisk perceptionCarcinomaRecurrence
2012
Body image in recently diagnosed young women with early breast cancer
Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH. Body image in recently diagnosed young women with early breast cancer. Psycho-Oncology 2012, 22: 1849-1855. PMID: 23132765, PMCID: PMC3594059, DOI: 10.1002/pon.3221.Peer-Reviewed Original ResearchConceptsCancer Rehabilitation Evaluation SystemMean CARE scoreCare scoresYoung womenBreast cancerMore body image concernsBody image concernsSurgical decision-making processMusculoskeletal pain symptomsProspective cohort studyEarly breast cancerBody imageWomen age 40Impact of treatmentImage concernsRehabilitation Evaluation SystemPotential future interventionsBreast cancer diagnosisMulti-variable analysisLumpectomy groupPain symptomsRadical surgeryCohort studySurgery typePsychological factorsBiomarkers of amenorrhea and ovarian function in breast cancer survivors.
Ruddy K, Gelber S, Tamimi R, Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. DOI: 10.1200/jco.2012.30.15_suppl.9071.Peer-Reviewed Original ResearchAnti-Mullerian hormoneBreast cancer survivorsOvarian functionBreast cancerCancer survivorsProspective multi-center cohort studyFollicle-stimulating hormone levelsMulti-center cohort studyYoung breast cancer survivorsResidual ovarian functionEarly breast cancerLast menstrual periodWilcoxon rank sum testRank sum testOvarian ablationEndocrine therapyOvarian suppressionCohort studyEligible womenFSH levelsOvarian reserveMedian ageOvarian dysfunctionSurvivorship periodMenopausal symptomsSexual functioning in young women with breast cancer.
Rosenberg S, Tamimi R, Gelber S, Ruddy K, Kereakoglow S, Borges V, Come S, Schapira L, Winer E, Partridge A. Sexual functioning in young women with breast cancer. Journal Of Clinical Oncology 2012, 30: 9100-9100. DOI: 10.1200/jco.2012.30.15_suppl.9100.Peer-Reviewed Original ResearchCancer Rehabilitation Evaluation SystemBreast cancerSexual functioningYoung womenMulti-center cohort studySexual interestRehabilitation Evaluation SystemBody imageAdjuvant therapyPain symptomsCohort studyDysfunction scorePoor body imageMusculoskeletal painSurvivorship periodMenopausal symptomsPoor functionCare scoresSexual dysfunctionActive womenStage 0Age 40Treatment groupsTreatment dataMultivariate analysis
2011
P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer.
Tracy M, Meyer M, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come S, Winer E, Partridge A. P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer. Cancer Research 2011, 71: p4-11-10-p4-11-10. DOI: 10.1158/0008-5472.sabcs11-p4-11-10.Peer-Reviewed Original ResearchContralateral prophylactic mastectomyContralateral breast cancerBreast cancerBilateral mastectomyYoung womenProphylactic mastectomyBenefits of CPMEarly breast cancerBilateral breast cancerSurgical treatment decisionsLongitudinal cohort studyBreast cancer treatmentPercent of womenCohort studyContralateral diseaseMedian ageProphylactic indicationsPatient preferencesTreatment decisionsMutation carriersAge 40MastectomyCancerCancer ResCancer treatmentP4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.
Collins L, Gelber S, Marotti J, Cole K, Kereakoglow S, Ruddy K, Brachtel E, Schapira L, Come S, Borges V, Schedin P, Warner E, Winer E, Partridge A. P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy. Cancer Research 2011, 71: p4-11-12-p4-11-12. DOI: 10.1158/0008-5472.sabcs11-p4-11-12.Peer-Reviewed Original ResearchNulliparous young womenBreast cancerYoung womenLast pregnancyParous womenNulliparous womenTumor gradeLarge cohortBreast cancer molecular phenotypesPregnancy-associated breast cancerOngoing prospective cohort studyMolecular phenotypesLuminal B cancersCentral pathology reviewProspective cohort studyMonths of diagnosisTriple-negative cancersBreast cancer riskGenomic alterationsHER2 typeParous breastPrior pregnancyB cancersCohort studyMedian agePD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery.
Rosenberg S, Tamimi R, Gelber S, Kereakoglow S, Borges V, Come S, Schapira L, Winer E, Partridge A. PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery. Cancer Research 2011, 71: pd04-05-pd04-05. DOI: 10.1158/0008-5472.sabcs11-pd04-05.Peer-Reviewed Original ResearchCare scoresBreast cancerYoung womenConcurrent treatmentTreatment groupsMulti-center prospective cohort studyHormone treatmentYoung breast cancer patientsBody image issuesMean CARE scoreBody imageProspective cohort studyBreast cancer patientsImpact of chemotherapyStage of diseaseTreatment-associated differencesImpact of treatmentHormonal therapyCohort studyHormone therapyRadical surgerySurgical groupMedian ageMedian timeUnadjusted analyses